ES2073653T3 - Derivados de adenosina 2-substituidos y composiciones farmaceuticas para las enfermedades del sistema circulatorio. - Google Patents

Derivados de adenosina 2-substituidos y composiciones farmaceuticas para las enfermedades del sistema circulatorio.

Info

Publication number
ES2073653T3
ES2073653T3 ES91120461T ES91120461T ES2073653T3 ES 2073653 T3 ES2073653 T3 ES 2073653T3 ES 91120461 T ES91120461 T ES 91120461T ES 91120461 T ES91120461 T ES 91120461T ES 2073653 T3 ES2073653 T3 ES 2073653T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
diseases
substituted adenosine
circulatory system
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91120461T
Other languages
English (en)
Inventor
Takanori Miyashita
Toichi Abiru
Yoko Watanabe
Toyofumi Yamaguchi
Akira Matsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamasa Shoyu KK
Original Assignee
Yamasa Shoyu KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP3-34249A external-priority patent/JP3025541B2/ja
Application filed by Yamasa Shoyu KK filed Critical Yamasa Shoyu KK
Application granted granted Critical
Publication of ES2073653T3 publication Critical patent/ES2073653T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE EXPONEN NUEVOS DERIVADOS DE LA ADENOSINA 2-SUSTITUIDA DE LA FORMULA (I) SIGUIENTE: DONDE R REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO HIDROXILO, M ES UN NUMERO ENTERO DE 2 A 7, N ES 0 O UN NUMERO ENTERO DE 1 A 3, Y R ELEVADO 1, R (AL CUADRADO) Y R ELEVADO 3, QUE PUEDEN SER IGUALES O DISTINTAS, CADA UNA DE ELLAS INDEPENDIENTEMENTE REPRESENTAN UN ATOMO DE HIDROGENO, UN GRUPO PROTECTOR HIDROXILO O UN RESIDUO DE ACIDO FOSFORICO Y LAS SALES DEL MISMO. LOS COMPUESTOS ANTES MENCIONADOS TIENEN UN EFECTO MEJORADOR DE LA CIRCULACION TAL COMO UNA ACTIVIDAD VASODEPRESORA, Y TIENEN ALTA SELECTIVIDAD PARA LOS RECEPTORES A SUB 2, PERO OCASIONAN MENORES EFECTOS COLATERALES SECUNDARIOS NO DESEADOS TAL COMO EFECTOS SUPRESORES EN EL CORAZON. SON, POR LO TANTO, EFECTIVOS CUANDO SE UTILIZAN EN COMPUESTOS FARMACEUTICOS PARA ENFERMEDADES CIRCULATORIAS.
ES91120461T 1990-11-30 1991-11-29 Derivados de adenosina 2-substituidos y composiciones farmaceuticas para las enfermedades del sistema circulatorio. Expired - Lifetime ES2073653T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33727390 1990-11-30
JP3-34249A JP3025541B2 (ja) 1990-11-30 1991-02-28 ２−置換アデノシン誘導体および循環器疾患用薬

Publications (1)

Publication Number Publication Date
ES2073653T3 true ES2073653T3 (es) 1995-08-16

Family

ID=26373034

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91120461T Expired - Lifetime ES2073653T3 (es) 1990-11-30 1991-11-29 Derivados de adenosina 2-substituidos y composiciones farmaceuticas para las enfermedades del sistema circulatorio.

Country Status (6)

Country Link
US (1) US5189027A (es)
EP (1) EP0488336B1 (es)
AT (1) ATE122355T1 (es)
CA (1) CA2056596C (es)
DE (1) DE69109631T2 (es)
ES (1) ES2073653T3 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852000A (en) * 1993-08-25 1998-12-22 Otsuka Pharmaceutical Factory, Inc. Cardiac rehabilitation agent
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5817641A (en) * 1994-07-21 1998-10-06 Thomas Jefferson University Treatment of enterotoxigenic diarrhea with 2-substituted adenosine derivatives
AU740770B2 (en) 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
AU2001238665A1 (en) * 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
AU2001278708A1 (en) 2000-09-08 2002-03-22 Toa Eiyo Ltd. Adenosine derivatives and use thereof
AU2001284485A1 (en) * 2000-09-08 2002-03-22 Toa Eiyo Ltd. Adenosine derivatives and use thereof
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
SG176313A1 (en) * 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
AU2002359732A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
JP2004018453A (ja) * 2002-06-14 2004-01-22 Sumika Fine Chemicals Co Ltd アルキニルプリン化合物およびその製造方法
AU2003259264A1 (en) * 2002-07-29 2004-02-16 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
JP2007531729A (ja) * 2004-04-02 2007-11-08 アデノシン、セラピューティックス、リミテッド、ライアビリティ、カンパニー Ａ２ａアデノシンレセプターの選択的アンタゴニスト
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
CA2576826C (en) * 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
CN101076343A (zh) * 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
EP2581381A3 (en) 2006-02-03 2013-10-30 Gilead Sciences, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
EP2068850A1 (en) * 2006-06-22 2009-06-17 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
WO2008028140A1 (en) * 2006-09-01 2008-03-06 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
CA2673653A1 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
WO2010037122A1 (en) * 2008-09-29 2010-04-01 Gilead Palo Alto, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
NZ703992A (en) 2012-08-01 2018-04-27 Lewis And Clark Pharmaceuticals Inc N-alkyl 2-(disubstituted)alkynyladenosine-5’-uronamides as a2a agonists
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299395A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
PT86660B (pt) 1987-02-04 1992-02-28 Ciba Geigy Ag Processo para a preparacao de derivados de adenosina-5'-carboxamida
US4992427A (en) * 1987-06-29 1991-02-12 University Of Iowa Research Foundation 2-substituted inosines and their use as antiviral agents
JPS6433477A (en) 1987-07-29 1989-02-03 Sanyo Electric Co Absorption heat pump device
US5034381A (en) 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
JPH0217526A (ja) 1988-07-06 1990-01-22 Canon Inc 印刷装置
EP0429681B1 (en) 1989-06-20 1995-09-06 Yamasa Shoyu Kabushiki Kaisha (Yamasa Corporation) Intermediate for 2-alkynyladenosine synthesis, production of said intermediate, production of 2-alkynyladenosine from said intermediate, and stable 2-alkynyladenosine derivative

Also Published As

Publication number Publication date
CA2056596C (en) 2001-08-21
CA2056596A1 (en) 1992-05-31
EP0488336B1 (en) 1995-05-10
US5189027A (en) 1993-02-23
EP0488336A1 (en) 1992-06-03
DE69109631D1 (de) 1995-06-14
DE69109631T2 (de) 1995-09-07
ATE122355T1 (de) 1995-05-15

Similar Documents

Publication Publication Date Title
ES2073653T3 (es) Derivados de adenosina 2-substituidos y composiciones farmaceuticas para las enfermedades del sistema circulatorio.
ES514877A0 (es) "un procedimiento para preparar derivados de purina".
ES505960A0 (es) Un procedimiento para la obtencion de un derivado acilico sustituido del compuesto acido 1,2,3,4-tetrahidro-3-isoqui- nolein-carboxilico
DE68925223D1 (de) 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-en-2-carbonsäure-Verbindungen
FI810604L (fi) Foerfarande foer framstaellning av indanderivat
ES2053754T3 (es) Estimulacion de macrofagos por un compuesto homologo o analogo de quadrol.
FI853866L (fi) 2-pyridin-tiol-derivat, foerfarande foer framstaellning av dessa samt farmaceutiska foereningar innehaollande dessa.
DE3882623T2 (de) Phosphorsaeurediester und salze davon.
DE69420514D1 (de) Cyclopropan-Derivate und diese enthaltende antivirale Mittel
IE873442L (en) Cephalosporin derivative
ATE135689T1 (de) 1,2,3,6-tetrahydronpyridinderivate
ES2058315T3 (es) Compuestos eficaces contra insuficiencia cerebral.
ATE4717T1 (de) Vincaminderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 488336

Country of ref document: ES